Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Herbal blend STW 5-II could soothe stomach pain without drugs

NCT ID NCT07198243

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a herbal medicine called STW 5-II can reduce inflammation in the gut lining and ease symptoms like stomach pain, bloating, and fullness after eating in people with functional dyspepsia. About 100 adults will take either the herbal remedy or a placebo for 8 weeks, with tissue samples and symptom diaries used to measure effects. An optional 4-week treatment extension is available for all participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
STW 5-II (a blend of six herbal extracts: bitter candy tuft, chamomile, caraway, melissa, peppermint, and licorice root)
What this could lead to
If successful, this could point toward a natural, well-tolerated option for managing functional dyspepsia symptoms and reducing gut inflammation.
What could go wrong
This is a small, early proof-of-concept trial. The herbal mixture may not outperform placebo, and results may not apply to all patients. Side effects are possible but typically mild.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion Criteria: Inclusion criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion criteria: * Major active somatic or psychiatric condition that may explain dyspeptic symptoms (stable dose of single antidepressant allowed for psychiatric indication, no limitation for other indications) Predominant symptoms of gastro-esophageal reflux disease (GERD) or irritable bowel syndrome (IBS) * Chronic ppi use. No PPI use for at least the prior 4 weeks before entering the trial- History of major abdominal surgery (except for appendectomy, cholecystectomy or splenectomy) * History or presence of diabetes mellitus type 1 \& type 2, coeliac disease or inflammatory bowel disease * Active malignancy * Known HIV, HBV or HCV infection * Significant alcohol use (\>10 units/weeks) * Females pregnant or lactating * Hypersensitivity against ingredients of STW 5-II or placebo (see annex) * Abnormal baseline laboratory blood values

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Functional dyspepsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospitals Leuven / UZLeuven

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.